Boundless Bio, Inc. (BOLD): restructuring charge — Boundless Bio restructures pipeline, cuts workforce 33%, discontinues BBI-355 monotherapy

Boundless Bio, Inc.

Workforce reduction of ~1/3; expects $1.2M one-time costs, substantially completed in Q2 2025.
Discontinues current POTENTIATE trial arms for BBI-355 due to narrow therapeutic index and poor tolerability.
Plans to develop BBI-355/BBI-825 combination; initial clinical data expected within extended cash runway.
Selects BBI-940 as Kinesin program candidate; IND submission expected first half 2026.
Cash, equivalents & investments $138.3M as of March 31, 2025; operating runway extended into first half 2028.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Boundless Bio, Inc. announced a restructuring with charges of approximately $1.2 million (approximately one-third of the Company’s workforce).

Type: restructuring
Charge: approximately $1.2 million
Headcount: approximately one-third of the Company’s workforce

Exact text from the filing

On May 23, 2025, Boundless Bio, Inc. (the Company), in connection with the portfolio prioritization described below, announced a workforce reduction of approximately one-third of the Company’s workforce. The Company expects to incur one-time costs of approximately $1.2 million in connection with the workforce reduction primarily related to one-time termination benefits (some of which are contractual), including severance and healthcare related benefits.

View on SEC.gov

Browse all restructurings & charges →

Boundless Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-076911

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.